Back

Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a double-blind, randomised, controlled phase 3 trial

2021-07-02 infectious diseases Title + abstract only
View on medRxiv
Show abstract

BackgroundWe report the clinical efficacy against COVID-19 infection of BBV152, a whole-virion inactivated SARS-CoV-2 vaccine formulated with a Toll-like receptor 7/8 agonist molecule adsorbed to alum (Algel-IMDG). MethodsWe did a double-blind, randomised, multicentre, phase 3 clinical trial in 25 Indian hospitals to evaluate the efficacy, safety, and immunological lot consistency of BBV152. Healthy adults (age 18-98 years) randomised 1:1 using a computer-generated randomisation scheme received...

Predicted journal destinations

1
New England Journal of Medicine
49 training papers
#1 21.2%
2
Vaccine
140 training papers
Top 1% 10.5%
3
Clinical Infectious Diseases
219 training papers
Top 2% 8.6%
4
Nature Communications
483 training papers
Top 17% 6.1%
5
The Lancet Infectious Diseases
57 training papers
Top 0.3% 4.8%
6
BMJ Open
553 training papers
Top 34% 4.8%
7
Open Forum Infectious Diseases
124 training papers
Top 2% 4.8%
8
Vaccines
131 training papers
Top 3% 4.0%
9
The Journal of Infectious Diseases
137 training papers
Top 3% 3.7%
10
PLOS ONE
1737 training papers
Top 90% 2.7%
11
BMJ
49 training papers
Top 1% 1.8%
12
PLOS Medicine
95 training papers
Top 6% 1.8%
13
Nature Medicine
88 training papers
Top 3% 1.8%
14
JAMA Network Open
125 training papers
Top 10% 1.8%
15
BMC Medicine
155 training papers
Top 18% 1.5%
16
International Journal of Infectious Diseases
115 training papers
Top 13% 1.5%
17
eClinicalMedicine
55 training papers
Top 3% 1.1%
18
Journal of Infection
64 training papers
Top 7% 1.1%
19
Clinical Microbiology and Infection
54 training papers
Top 6% 1.1%
20
Emerging Infectious Diseases
84 training papers
Top 14% 0.9%
21
Frontiers in Immunology
140 training papers
Top 14% 0.7%
22
Scientific Reports
701 training papers
Top 95% 0.7%
23
Eurosurveillance
77 training papers
Top 15% 0.7%